Laboratory assay overview
Assessment of liver status following a diagnosis of HCV. Baseline determination of liver status before initiating HCV therapy. Posttreatment assessment of liver status six months after completion of therapy. Noninvasive assessment of liver status in patients who are at increased risk of complications from a liver biopsy.
Labcorp population reference ranges
Labcorp calculates these statistical intervals for this specific assay and demographic group, not as universal optimal targets.
| Population | Range |
|---|
| Fibrosis Stage (FibroTest) | Range |
| F0−No fibrosis | 0.00−0.21 |
| F0−F1 | >0.21−0.27 |
| F1−Portal fibrosis | >0.27−0.31 |
| F1−F2 | >0.31−0.48 |
| F2−Bridging fibrosis with few septa | >0.48−0.58 |
| F3−Bridging fibrosis with many septa | >0.58−0.72 |
| F3−F4 | >0.72−0.74 |
| F4−Cirrhosis | >0.74−1.00 |
| Activity Stage (ActiTest) | Range |
| A0−No activity | 0.00−0.17 |
| A0−A1 | >0.17−0.29 |
| A1−Minimal activity | >0.29−0.36 |
| A1−A2 | >0.36−0.52 |
| A2−Moderate activity | >0.52−0.60 |
| A2−A3 | >0.60−0.63 |
| A3−Severe activity | >0.63−1.00 |
View complete laboratory reference notes
See tables.
METAVIR Group Scoring System
Fibrosis Stage (FibroTest) | Range
F0−No fibrosis | 0.00−0.21
F0−F1 | >0.21−0.27
F1−Portal fibrosis | >0.27−0.31
F1−F2 | >0.31−0.48
F2−Bridging fibrosis with few septa | >0.48−0.58
F3−Bridging fibrosis with many septa | >0.58−0.72
F3−F4 | >0.72−0.74
F4−Cirrhosis | >0.74−1.00
Activity Stage (ActiTest) | Range
A0−No activity | 0.00−0.17
A0−A1 | >0.17−0.29
A1−Minimal activity | >0.29−0.36
A1−A2 | >0.36−0.52
A2−Moderate activity | >0.52−0.60
A2−A3 | >0.60−0.63
A3−Severe activity | >0.63−1.00